Réutilisation maîtrisée des eaux usées : approfondir les connaissances pour lever les freins et relever les défis

Le recyclage des eaux usées représente une solution pour faire face à la demande croissante des ressources hydriques pour l’irrigation agricole. Mais leur réutilisation pose des problèmes de sécurité, de réglementation et bien sûr de techniques adaptées, que cet article nous propose de mieux comprendre

Evolution of Ossoue Glacier (French Pyrenees) since the end of the Little Ice Age

International audienceLittle is known about the fluctuations of the Pyre-nean glaciers. In this study, we reconstructed the evolution of Ossoue Glacier (42 • 46 N, 0.45 km 2), which is located in the central Pyrenees, from the Little Ice Age (LIA) onwards. To do so, length, area, thickness, and mass changes in the glacier were generated from historical data sets, topo-graphical surveys, glaciological measurements (2001–2013), a ground penetrating radar (GPR) survey (2006), and stereo-scopic satellite images (2013). The glacier has receded considerably since the end of the LIA, losing 40 % of its length and 60 % of its area

Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming

Components of the SWI/SNF chromatin remodeling complex, including BRG1 (also SMARCA4), are inactivated in cancer. Among other functions, SWI/SNF orchestrates the response to retinoid acid (RA) and glucocorticoids (GC) involving downregulation of MYC. The epigenetic drugs SAHA and azacytidine, as well as RA and GC, are currently being used to treat some malignancies but their therapeutic potential in lung cancer is not well established. Here we aimed to determine the possible therapeutic effects of azacytidine and SAHA (A/S) alone or in combination with GC plus RA (GC/RA) in lung cancers with either BRG1 inactivation or MYC amplification. In vitro, responses to GC/RA treatment were more effective in MYC-amplified cells. These effects were mediated by BRG1 and involved a reprogramming towards prodifferentiation gene expression signatures and downregulation of MYC. In MYC-amplified cells, administration of GC/RA enhanced the cell growth inhibitory effects of A/S which, in turn, accentuated the prodifferentiation features promoted by GC/RA. Finally, these treatments improved overall survival of mice orthotopically implanted with MYC-amplified, but not BRG1-mutant, cells and reduced tumor cell viability and proliferation. We propose that the combination of epigenetic treatments with retinoids and corticoids of MYC-driven lung tumors constitute a strategy for therapeutic intervention in this otherwise incurable disease

Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors

Background: Cisplatin (CDDP) resistance in testicular germ cell tumors (GCTs) is still a clinical challenge, and one associated with poor prognosis. The purpose of this work was to test pazopanib, an anti-tumoral and anti-angiogenic multikinase inhibitor, and its combination with lapatinib (an anti-ErbB inhibitor) in mouse orthotopic models of human testicular GCTs. Methods: We used two different models of human testicular GCTs orthotopically grown in nude mice; a CDDP-sensitive choriocarcinoma (TGT38) and a new orthotopic model generated from a metastatic GCT refractory to first-line CDDP chemotherapy (TGT44). Nude mice implanted with these orthotopic tumors were treated with the inhibitors and the effect on tumoral growth and angiogenesis was evaluated. Results: TGT44 refractory tumor had an immunohistochemical profile similar to the original metastasis, with characteristics of yolk sac tumor. TGT44 did not respond when treated with cisplatin. In contrast, pazopanib had an anti-angiogenic effect and anti-tumor efficacy in this model. Pazopanib in combination with lapatinib in TGT38, an orthotopic model of choriocarcinoma had an additive effect blocking tumor growth. Conclusions: We present pazopanib as a possible agent for the alternative treatment of CDDP-sensitive and CDDP-refractory GCT patients, alone or in combination with anti-ErbB therapies

Problemas éticos en el almacenamiento y la utilización de muestras biológicas

Mostres biològiques; Consentiment informat; Donació de teixitsMuestras biológicas; Consentimiento informado; Donación de tejidosBiological samples; Informed consent; Donation of tissuesL'objectiu d'aquest document és presentar aspectes generals amb relació a les mostres biològiques i tractar, amb més detall, les qüestions rellevants pel que fa al consentiment informat (necessari o no necessari), la confidencialitat de les mostres, i la qualitat de l’obtenció i la conservació: emmagatzematge (bancs i arxius)